Latest News

Kevin Huttman Appointed the Company’s First Chief Marketing Officer (CMO)

San Diego, CA February 13, 2017– iAssay, Inc. announces that Kevin Huttman has been appointed the Company’s first Chief Marketing Officer (CMO), joining the point of care medical device provider's leadership team,  reporting to Lonnie Adelman, CEO.

Kevin Huttman is a global business leader that has commercialized eleven (11) separate technology platforms spanning the Dx – Diagnostic testing market, along with dozens of new product launches. Most recently, at Diagnostic Architects, a Greenfield Start-up Disposable Medical Device Company that designed, developed, and manufactured MDx immunoassay tests for major channel powers, securing key licensing agreements.

Adelman said: “We have reached a new level of success at iAssay.  We are indeed fortunate to have Kevin working with us to skillfully guide us into the marketplace, and work with the team to drive our business and brand to the next level.”

Previously, Mr. Huttman spent 10 years as Division President of DuPont’s Dx-molecular based products. While leading DuPont Qualicon, the Business Unit achieved global market share leadership position; a position gained starting with a technology idea out of Central R&D. This SBU commercialized multiple Dx testing platforms employing PCR, RT-PCR, and bacteriophage technologies, along with next-gen genomic sequencing, genetic screening and diagnostics. Mr. Huttman has worked with key opinion leaders around the globe in the Dx arena. He has been to 41 countries, opening commercial operations throughout the world. Prior to DuPont, he was a member of the core leadership team at IDEXX Labs from start-up to successful IPO. Mr. Huttman began his career at Abbott Laboratories Diagnostics Division; he was awarded Marketing Manager of the Year while launching multiple Oncology diagnostic markers. At Abbott, he also led the US Government Accounts program where he simplified reimbursement for military and public health accounts simplifying the purchasing process.   Mr. Huttman has presented to Fortune 100 BODs, customer audiences in the thousands, and executive management at investment firms around the globe.   Huttman brings extensive experience in the Dx – Diagnostic testing market, along with dozens of new product launches. He has worked in the US and has been to 41 countries, opening commercial operations throughout the world.

Huttman said: “This is an extremely exciting time for iAssay.  The need for Point of Care testing is growing by leaps and bounds, and I see iAssay filling that need.  It’s great being a part of history in the making!”

About iAssay

The iAssay® System (patents pending) is the world’s 1st Open Platform for wirelessly-connected Point of Care diagnostics.  The functionality of a closet full of single function readers is replaced by a single handheld device and adaptor plug-ins, to adapt nearly any Point of Care test cartridge to the iAssay® System. The device HIPAA-compliantly aggregates test/patient/wearables data and pushes all data into The Cloud.  iAssay eliminates multiple daily trips with blood samples to central labs by testing the patient wherever they are. Testing at a clinic or at the patients’ bedside in a few minutes eliminates test result delays (and delayed diagnosis), eliminates sample handling and transportation costs, improves patient outcomes, and saves the healthcare system money.